CDK12 and cancer: This observation allowed us to estimate the critical time point in the advancement of GP5 cancer when the TD phenotype became active due to biallelic inactivation of CDK12 [61, 62], placing it at approximately 50 years of age, after ~ 75% of the MRCA mutations had occurred.